<DOC>
	<DOCNO>NCT01057069</DOCNO>
	<brief_summary>This study aim compare response triple-negative breast cancer deficient homologous recombination intensify alkylating chemotherapy versus standard chemotherapy dose dense AC and/or Docetaxel-Capecitabine .</brief_summary>
	<brief_title>Neo Adjuvant Chemotherapy Triple Negative Breast Cancer</brief_title>
	<detailed_description>Homologous Recombination ( HR ) DNA repair mechanism repair double-strand DNA break . It reliable repair mechanism repair consequence DNA adduct cause bifunctional alkylating agent ( cyclophosphamide , thiotepa carboplatin ) . Alternative DNA repair mechanism exist , unavoidably induce DNA mutation , deletion chromosome aberration , give give rise genetic instability . HRD may consequence inactivation BRCA-1 BRCA-2 gene ( hereditary breast cancer ) , may also cause defect Fanconi anemia pathway amplification EMSY gene . HRD present breast cancer cell healthy cell BRCA-1 BRCA-2 mutation carrier , also half sporadic triple-negative breast cancer . This phase II/III control multicenter trial investigate ability individualize chemotherapy improve objective response rate 'triple-negative ' breast cancer ( estrogen receptor progesterone receptor-negative , HER2 amplification ) preoperative ( neoadjuvant ) chemotherapy . It answer question whether intensified alkylating chemotherapy improve response rate tumor Homologous Recombination Defect ( HRD ) gather data require design phase III study document efficacy response monitor contrast-enhanced MRI TN breast cancer without HRD .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<criteria>Proven infiltrate breast cancer either primary tumor 2 cm size ( MRI ultrasound examination ) and/or cytologically prove spread axillary lymph node . Patients 'locally advance breast cancer ' consequently eligible , include ipsilateral supraclavicular lymph node metastasis . The tumor must HER2/neunegative ( either score 0 1 immunohistochemistry negative situ hybridization [ CISH FISH ] case score 2 3 immunohistochemistry ) . The tumor must Estrogen receptor ( ER ) negative ( &lt; 10 % nuclear stain IHC ) Progesterone receptor ( PR ) negative ( &lt; 10 % nuclear stain IHC ) . However , rare tumor ERnegative PRpositive eligible , pattern hormone receptor expression verify NKIAVL reference pathology lab . Age 18 59 year ; patient older 59 year may include consider 'biologically 59 year young ' ( judged investigator ) . Performance status : WHO 0 I . Adequate bone marrow function ( W.B.C . count &gt; 3.0 x 109/l , platelet &gt; 100 x 109/l ) . Adequate hepatic function ( ALAT , ASAT bilirubin &lt; 2 x upper limit normal , minor abnormality test judge consequence study coordinator ) . Adequate renal function ( creatinine clearance &gt; 60 ml/min ) . Informed consent Previous radiation therapy chemotherapy . Other malignancy except carcinoma situ , unless malignancy treat 5 year ago curative intent without use chemotherapy radiation therapy . Pregnancy breast feed . Evidence distant metastasis . Staging examination must include chest roentgenogram , ultrasound examination liver isotope bone scan . Abnormal uptake isotope bone scan accept bone metastasis exclude MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Neo adjuvant</keyword>
	<keyword>Triple negative</keyword>
	<keyword>primary tumor 2 cm and/or positive lymphnodes</keyword>
</DOC>